Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure.
about
A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disordersInnovation attributes and adoption decisions: perspectives from leaders of a national sample of addiction treatment organizations.Challenges to providing quality substance abuse treatment services for American Indian and Alaska Native communities: perspectives of staff from 18 treatment centers.Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuationOrganizational Predictors and Use of Evidence-Based Practices in Adolescent Substance Abuse TreatmentImplementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programsHow do providers serving American Indians and Alaska Natives with substance abuse problems define evidence-based treatment?Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.Access to Addiction Pharmacotherapy in Private Health Plans.Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programsLongitudinal Examination of Medical Staff Utilization in Substance Use Disorder Treatment OrganizationsFinancial factors and the implementation of medications for treating opioid use disorders.Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.Rural substance use treatment centers in the United States: an assessment of treatment quality by locationUse of evidence-based treatments in substance abuse treatment programs serving American Indian and Alaska Native communities.Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatmentThe transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.Integration of Care in the Implementation of the Affordable Care Act: Changes in Treatment Services in a National Sample of Centers Treating Substance Use Disorders.A demonstration project implementing extended-release naltrexone in Los Angeles County.Combining medically assisted treatment and Twelve-Step programming: a perspective and review.Medical students' attitudes on and experiences with evidence-based medicine: a qualitative study.Promoting Adoption of Medication for Opioid and Alcohol Use Disorders Through System Change.Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.Extended release naltrexone for alcohol use disorders: quasi-experimental effects on mortality and subsequent detoxification episodes.Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities.Opioid recovery initiation: Pilot test of a peer outreach and modified Recovery Management Checkup intervention for out-of-treatment opioid users.Attitudes toward evidence-based pharmacological treatments among community-based addiction treatment programs targeting vulnerable patient groups.
P2860
Q27000732-C827CFAD-17CB-4544-A94A-3C3872F4C098Q30366758-C0021B43-E392-4B03-8076-78FEB912A1E4Q33841327-916029F3-368E-42F4-86FB-F3BEDDD7759DQ33949899-C689F009-3630-4178-BE17-0C17EB5081DCQ34925449-8FD0D184-C14D-4F70-A2C0-C01A8791C0EAQ35075932-7F12958F-A947-45AF-B6E3-021E59841166Q35217803-08784F4F-F8F0-4D54-B592-3F1ED36C7880Q35400440-0CE4A01F-140D-4ACC-AAAA-F79FA7242B36Q35447234-34FF69E3-859C-427D-A837-D969C9522E87Q35602408-7983B7F0-CCF2-4C56-B983-A4948A35EC98Q35937004-231D8C77-BD03-429B-82C7-20358E2ECC25Q36025907-275968E0-99AC-4061-A5CB-C1D98EF0CC8FQ36129595-89BB6D5D-7B3F-449C-86D6-659D3AC3376AQ36322546-AF58CDA0-AE6D-4833-9734-E7300317B933Q36381418-ACB11CC7-7747-4EE0-8CEC-C700BDBAB258Q36597560-3E1B60E1-5673-4FCC-B658-8398CE30FC74Q36643013-AB1F0AC3-CC67-4571-95C2-65371B60AFDBQ36757250-80034415-4657-4F19-A55E-E295045A81ADQ37272343-AEE2025E-0BCC-4AAD-979A-F9E46FA987D1Q37729027-F6A8DD94-9980-4447-887C-7628C08CC0F3Q38838575-90D125F9-69F2-4939-B61F-2AADD5CA9E19Q38871371-F5C57116-36C0-4DA1-9B48-04143440C7D8Q38986525-327E5224-1DCA-4E01-BF74-F47162477F5BQ39226314-2BEE33D6-2760-4371-AB06-9D8D83BAD135Q43736206-96EF13BD-E4DB-4031-AB2E-8B66E8DB0A81Q44349044-C667D059-1D95-4E2D-AD31-9E30CFA12AA9Q44350841-242B71E4-23E3-4565-885F-1C3427892B0BQ44350939-0703AA2F-13B7-461D-83F1-2B33C6E01996Q45938302-769C1CFB-9420-4045-BE17-D871D13BD600Q47561425-D9723422-A57F-4603-9BC0-338BF077E386Q50054974-5A64E587-8209-4146-8278-911A09C285DAQ50782070-AA7FFD2A-DDBE-4E79-BF90-2A18EE2190A9
P2860
Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Barriers to the implementation ...... es and medical infrastructure.
@en
type
label
Barriers to the implementation ...... es and medical infrastructure.
@en
prefLabel
Barriers to the implementation ...... es and medical infrastructure.
@en
P2093
P2860
P1476
Barriers to the implementation ...... es and medical infrastructure.
@en
P2093
Amanda J Abraham
Carrie B Oser
Hannah K Knudsen
P2860
P304
P356
10.1016/J.EVALPROGPLAN.2011.02.004
P577
2011-03-02T00:00:00Z